San Leandro, CA, United States of America

Volkmar Guenzler-Pukall

This inventor holds 27 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 10 EPO patents, primarily in Biomedical Innovation. Top assignee: Fibrogen, Inc.. Active years: 2008-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Volkmar Guenzler-Pukall. Retrieved from https://idiyas.com/inventor/volkmar-guenzler-pukall

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 4)

% Patents Active = 74.1

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 6.3

ph-index = 10

Forward Citations = 343(Granted Patents)

Location History:

Emeryville, CA (US) (2012)
Kamakura, JP (2018)
San Leandro, CA (US) (2008 - 2022)
Marburg, DE (2020 - 2023)

Company Filing History:

27 out of 89

Fibrogen, Inc.

patents

Years Active: 2008-2023

Loading Chart...

Areas of Expertise:

Erythropoiesis

Iron Metabolism

Nitrogen-Containing Compounds

Heteroaryl Compounds

Hypoxia Inducible Factor

Fat Regulation

Diabetes Treatment

Compounds Use

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11680048 - Enhanced erythropoiesis and iron metabolism (2023-06-20),

2. 11680047 - Enhanced erythropoiesis and iron metabolism (2023-06-20),

3. 11229637 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2022-01-25),

4. 10927081 - Enhanced erythropoiesis and iron metabolism (2021-02-23),

5. 10894774 - Enhanced erythropoiesis and iron metabolism (2021-01-19),

6. 10882827 - Enhanced erythropoiesis and iron metabolism (2021-01-05),

7. 10646482 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2020-05-12),

8. 10626090 - Enhanced erythropoiesis and iron metabolism (2020-04-21),

9. 10092558 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2018-10-09),

10. 9920011 - Enhanced erythropoiesis and iron metabolism (2018-03-20),

11. 9339527 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2016-05-17),

12. 8916585 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2014-12-23),

13. 8765956 - Nitrogen-containing heteroaryl compounds and methods of use thereof (2014-07-01),

14. 8629131 - Enhanced erythropoiesis and iron metabolism (2014-01-14),

15. 8614204 - Enhanced erythropoiesis and iron metabolism (2013-12-24),

Title: Volkmar Guenzler-Pukall: Innovator in Erythropoiesis and Iron Metabolism

Introduction: Volkmar Guenzler-Pukall is a distinguished inventor based in San Leandro, California, known for his significant contributions in the field of biomedical innovations. With a remarkable total of 27 patents to his name, he has made notable advancements that impact the treatment of iron deficiency and anemia.

Latest Patents: Among his latest patents are groundbreaking inventions focused on enhancing erythropoiesis and iron metabolism. These inventions relate to methods and compounds designed to regulate or enhance erythropoiesis and iron metabolism, providing therapeutic avenues for treating and preventing iron deficiency and anemia of chronic disease.

Career Highlights: Volkmar Guenzler-Pukall is currently associated with Fibrogen, Inc., a prominent company in the biopharmaceutical sector. His work at Fibrogen reflects his dedication to developing innovative solutions for challenging medical conditions through research and application of advanced biotechnologies.

Collaborations: Throughout his career, Volkmar has collaborated closely with esteemed colleagues, including Stephen J. Klaus and Thomas B. Neff. These partnerships have allowed for the exchange of ideas and expertise, fostering an environment of innovation that has contributed to the success of their projects.

Conclusion: Volkmar Guenzler-Pukall is an influential figure in the fields of erythropoiesis and iron metabolism. His extensive patent portfolio and collaborative efforts highlight his commitment to innovation, ultimately benefiting patients suffering from iron-related health issues. His contributions at Fibrogen, Inc. continue to pave the way for advancements in treatment methodologies.

Profile summary based on public USPTO records.